TRU expands to Vietnam with Ministry of Health Approval

NZX Announcement

20 April 2020


Truscreen expands to Vietnam with Ministry of Health Approval
TruScreen Limited (NZX:TRU) (TruScreen or the “Company”) is pleased to advise that it has
received approval from the Ministry of Health (MOH) of the Vietnam Government for the
commercial roll out of the TruScreen cervical cancer screening device.
This landmark approval is granted initially for the Hanoi Obstetrics and Gynaecology Hospital
(HOGH). It is anticipated that further rollouts across other public and private hospitals in Vietnam
will occur this year.
The approval follows a MOH managed clinical trial covering 989 patients which was concluded
successfully with a positive clinical outcome at the HOGH. The trial compared the specificity and
sensitivity between the results from the TruScreen hand held real time screening device and Pap
test for the detection of cervical early stage pre-cancerous, and progressing intraepithelial
lesions. The outcome of the trial was assessed by the Vietnam Ministry of Health Professional
Advisory Committee which endorsed and approved the introduction of TruScreen cervical cancer
screening technology in Vietnam.
TruScreen CEO, Victoria Potarina comments, “The Vietnam government approval of TruScreen is a
significant milestone for the Company. Together with our local distributor, Gordon Health Services we have
been engaged on this project for over two years, in a review process that has been extremely thorough.

We look forward to working with HOGH and the MOH in improving the health and lives of women in
Vietnam.”

This announcement has been approved by the Board.

- ENDS -

For more information, visit www.truscreen.com or contact:
TruScreen
Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com


Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:
TruScreen is a Cervical Cancer Screening Device which
offers the latest technology in cervical screening,
providing real-time, accurate detection of pre-
cancerous and cancerous cervical cells to help improve
the health and well-being of women around the world.
TruScreen’s real-time cervical cancer technology
utilises a digital wand which is placed on the surface of
the cervix to measure electrical and optical signals from
the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous
change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing
issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and
the need for supporting laboratory infrastructures. As such, TruScreen’s target market is low-
and middle-income countries where no large-scale cervical cancer screening programs and
infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical
cancer screening device is CE-marked and certified for use throughout Europe and CFDA-
approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-
video/